N1-[2,2-Dimethyl-1(S)-(hydroxymethyl)propyl]-N4-hydroxy-2(R)-[3-[4-(pyridin-4-yl)phenyl]-1H-pyrrol-1-yl]succinamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: N1-[2,2-Dimethyl-1(S)-(hydroxymethyl)propyl]-N4-hydroxy-2(R)-[3-[4-(pyridin-4-yl)phenyl]-1H-pyrrol-1-yl]succinamide
• 英文别名: (2R)-N'-hydroxy-N-[(2S)-1-hydroxy-3,3-dimethylbutan-2-yl]-2-[3-(4-pyridin-4-ylphenyl)pyrrol-1-yl]butanediamide
• 化学式: C₂₅H₃₀N₄O₄
• 分子量: 450.5
• InChiKey: QTIVAWWGIDSOML-FGZHOGPDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  33
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  117
• 氢给体数：
  4
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  N4-t-butyldiphenylsiloxy-N1-[2,2-Dimethyl-1(S)-(hydroxymethyl)propyl]-2(R)-[3-[4-(pyridin-4-yl)phenyl]-1H-pyrrol-1-yl]succinamide 、 四丁基氟化铵 、 磷酸肌酸 在 resultant precipitate 、 水 、 乙醇 作用下， 以 四氢呋喃 为溶剂， 反应 1.25h， 以to yield 30 mg (42%) of N1-[2,2-Dimethyl-1(S)-(hydroxymethyl)propyl]-N4-hydroxy-2(R)-[3-[4-(pyridin-4-yl)phenyl]-1H-pyrrol-1-yl]succinamide as an amorphous solid, which的产率得到N1-[2,2-Dimethyl-1(S)-(hydroxymethyl)propyl]-N4-hydroxy-2(R)-[3-[4-(pyridin-4-yl)phenyl]-1H-pyrrol-1-yl]succinamide
  参考文献：
  名称：

  Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses

  摘要：

  本发明涉及化合物I的配方，其中R1、R2、R3、R4、R5、X、Y和β如下所定义。这些化合物通过将发明化合物的有效量与金属蛋白酶接触来抑制金属蛋白酶的活性。

  公开号：

  US06174915B1

文献信息

• Inhibitors of Hepatitis C virus, compositions and treatments using the same
  申请人：AGOURON PHARMACEUTICALS, INC.

  公开号：US20040229817A1

  公开（公告）日：2004-11-18

  The invention relates to methods of inhibiting HCV viral replication activity comprising contacting an HCV polymerase with a therapeutically effective amount of a hydroxamate MMP inhibitor, and compositions comprising the same.

  本发明涉及一种抑制丙型肝炎病毒复制活性的方法，包括将丙型肝炎病毒聚合酶与治疗有效量的羟肟酸基金属蛋白酶抑制剂接触，并包括这种组合物。
• Metalloproteinase inhibitors, pharmaceutical compositions containing
  申请人：Agouron Pharmaceuticals, Inc.

  公开号：US06008243A1

  公开（公告）日：1999-12-28

  The present invention is directed to compound of the formula I: ##STR1## wherein R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, X, Y, and ##STR2## are as defined herein. These compounds are useful for inhibiting the activity of a metalloproteinase by contacting the metalloproteinase with an effective amount of the inventive compounds.

  本发明涉及式I的化合物：##STR1## 其中R.sub.1、R.sub.2、R.sub.3、R.sub.4、R.sub.5、X、Y和##STR2##如本文所定义。这些化合物通过将发明化合物的有效量与金属蛋白酶接触来抑制金属蛋白酶的活性。
• Metalloproteinase inhibitors, pharmaceutical compositions containing them and their pharmaceutical uses
  申请人：Agouron Pharmaceuticals, Inc.

  公开号：US06174915B1

  公开（公告）日：2001-01-16

  The present invention is directed to compound of the formula I: wherein R1, R2, R3, R4, R5, X, Y, and  are as defined herein. These compounds are useful for inhibiting the activity of a metalloproteinase by contacting the metalloproteinase with an effective amount of the inventive compounds.

  本发明涉及化合物I的配方，其中R1、R2、R3、R4、R5、X、Y和β如下所定义。这些化合物通过将发明化合物的有效量与金属蛋白酶接触来抑制金属蛋白酶的活性。
• COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS
  申请人：WARNER-LAMBERT COMPANY

  公开号：EP1098662A2

  公开（公告）日：2001-05-16
• INHIBITORS OF HEPATITIS C VIRUS, COMPOSITIONS AND TREATMENTS USING THE SAME
  申请人：PFIZER INC.

  公开号：EP1596846A2

  公开（公告）日：2005-11-23